Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cytek Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Cytek Biosciences, Inc.’s stock price such as:

• Cytek Biosciences, Inc.’s current stock price and volume
• Why Cytek Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for CTKB from analysts
• CTKB’s stock price momentum as measured by its relative strength

About Cytek Biosciences, Inc. (CTKB)

Before we jump into Cytek Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Want to learn more about Cytek Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cytek Biosciences, Inc..

Cytek Biosciences, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 2:01 PM, CST, Cytek Biosciences, Inc.’s stock price was $4.225.

Cytek Biosciences, Inc. is down 1.97% from its previous closing price of $4.310.

During the last market session, Cytek Biosciences, Inc.’s stock traded between $4.135 and $4.310. Currently, there are approximately 128.70 million shares outstanding for Cytek Biosciences, Inc..

Cytek Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cytek Biosciences, Inc. Stock Price History

Cytek Biosciences, Inc.’s (CTKB) price is currently down 4.63% so far this month.

During the month of July, Cytek Biosciences, Inc.’s stock price has reached a high of $4.790 and a low of $4.135.

Over the last year, Cytek Biosciences, Inc. has hit prices as high as $6.180 and as low as $3.280. Year to date, Cytek Biosciences, Inc.’s stock is down 16.34%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cytek Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Cytek Biosciences, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cytek Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cytek Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Cytek Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cytek Biosciences, Inc. (CTKB) by visiting AAII Stock Evaluator.

Relative Price Strength of Cytek Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Cytek Biosciences, Inc. has a weighted four-quarter relative price strength of -0.32%, which translates to a Momentum Score of 50 and is considered to be Average.

Want to learn more about how Cytek Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cytek Biosciences, Inc. Stock Price: Bottom Line

As of July 31, 2026, Cytek Biosciences, Inc.’s stock price is $4.225, which is down 1.97% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cytek Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.